Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Sales and Divestitures (2018 - 2025)

Aytu Biopharma (AYTU) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $81119.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 7677.47% to $81119.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $81119.0, a 7677.47% increase, with the full-year FY2025 number at $1608.0, down 28.5% from a year prior.
  • Gains from Sales and Divestitures was $81119.0 for Q4 2025 at Aytu Biopharma, up from $1618.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $112787.0 in Q1 2022 to a low of $564.0 in Q3 2024.
  • A 5-year average of $25381.5 and a median of $9962.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 97.71% in 2023, then surged 7677.47% in 2025.
  • Aytu Biopharma's Gains from Sales and Divestitures stood at $90836.0 in 2021, then tumbled by 66.17% to $30733.0 in 2022, then plummeted by 60.34% to $12189.0 in 2023, then crashed by 91.44% to $1043.0 in 2024, then soared by 7677.47% to $81119.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Gains from Sales and Divestitures are $81119.0 (Q4 2025), $1618.0 (Q3 2025), and $1608.0 (Q2 2025).